Marc A Caporini

This inventor holds 8 USPTO granted patents and 2 published patent applications and 4 EPO patents. Top assignees: Amgen Inc., Bruker Biospin Ag, Ecole Polytechnique Federale De Lausanne. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marc A Caporini. Retrieved from https://idiyas.com/inventor/marc-a-caporini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 23(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2022)
Cambridge, MA (US) (2015 - 2024)
Belmont, MA (US) (2024)

Company Filing History:

Ecole Polytechnique Federale De Lausanne

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692266 - Synthesis of key intermediate of KRAS G12C inhibitor compound (2026-07-28),

2. 12473329 - Methods directed to crystalline biomolecules (2025-11-18),

3. 12391691 - Synthesis of key intermediate of KRAS G12C inhibitor compound (2025-08-19),

4. 12391689 - Synthesis of key intermediate of KRAS G12C inhibitor compound (2025-08-19),

5. 12000915 - Method for conducting solid state NMR on macromolecule-containing solid state formulations (2024-06-04),

6. 11958882 - Methods directed to crystalline biomolecules (2024-04-16),

7. 11299491 - Synthesis of key intermediate of KRAS G12C inhibitor compound (2022-04-12),

8. 8963546 - Method for NMR spectroscopy (2015-02-24),

Title: Innovations and Contributions of Marc A. Caporini

Introduction

Marc A. Caporini is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds targeting KRAS G12C mutations. With a total of 8 patents to his name, Caporini's work has been instrumental in advancing cancer treatment options.

Latest Patents

One of his latest patents focuses on the "Synthesis of key intermediate of KRAS G12C inhibitor compound." This invention relates to an improved, efficient, and scalable process to prepare intermediate compounds, such as compound 5M. These compounds are crucial for synthesizing drugs that target KRAS G12C mutations, which are associated with various cancers.

Career Highlights

Marc A. Caporini has established a successful career at Amgen Inc., a leading biotechnology company. His innovative approaches and dedication to research have positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Throughout his career, Caporini has collaborated with several talented individuals, including Andrew Thomas Parsons and William Powazinik. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Marc A. Caporini's contributions to the field of pharmaceutical chemistry and his innovative patents demonstrate his commitment to advancing medical science. His work continues to impact the development of targeted therapies for cancer treatment.

Profile summary based on public USPTO records.